Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00803634 · ClinicalTrials.gov registry record · Phase 3

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)

A Phase 3 study, sponsored by The Medicines Company.

Completed
Registry status
Phase 3
Development phase
117
Enrollment target

NCT00803634 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 117 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00803634, a Phase 3 study, has completed, sponsored by The Medicines Company.

COMPLETED
Registry status
Phase 3
Development phase
117 participants
Enrollment target

Study Summary

The purpose of this study was to evaluate the efficacy and safety of intravenous (IV) clevidipine as compared with standard of care IV antihypertensive agents for blood pressure (BP) lowering in patients with acute heart failure and elevated BP.

Interventions

  • DRUG Clevidipine
  • DRUG Standard of Care IV antihypertensive

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2008-12
Est. Completion 2012-03
Phase Phase 3

Sponsor

The Medicines Company

35 total trials

What the Registry Record Tells You About NCT00803634

The ClinicalTrials.gov registry entry for NCT00803634 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Clevidipine is the first listed.

NCT00803634 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00803634 about?

NCT00803634 is a clinical study titled "Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)". The purpose of this study was to evaluate the efficacy and safety of intravenous (IV) clevidipine as compared with standard of care IV antihypertensive agents for blood pressure (BP) lowering in patients with acute heart failure and elevated BP.

What is the current status of trial NCT00803634?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2008-12. Estimated completion is 2012-03.

What interventions are being tested in trial NCT00803634?

The interventions under investigation include: Clevidipine (DRUG), Standard of Care IV antihypertensive (DRUG).

Who is sponsoring clinical trial NCT00803634?

This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.